{"name":"BerGenBio ASA","slug":"bergenbio-asa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BGB149","genericName":"BGB149","slug":"bgb149","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BGB149","genericName":"BGB149","slug":"bgb149","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Lc3NBRFQ1MnJSVEFBaVFndGNHZWN3Y3dtNkNsVEFPTDJjNW8tTUNTV0NIY19lY25wNW1yRk9UdVlIa3J2RG5CREVQOFZNdVlaNFNGZ3VIalJzT0pUN2RJ?oc=5","date":"2025-10-02","type":"pipeline","source":"pharmatimes.com","summary":"Olav Hellebø - pharmatimes.com","headline":"Olav Hellebø","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPd1RwRm5ZTEIydW9sWUlKRzFfMTZpRFhvOUdYSHg2OC1CWVJhUlJFS2xjUklTNlR3R2R3T2FEclVmZjZ4UVRSelhDLVJUTjZlZWFNNjRNQllTRUtPYzZpRS1MWDdrb0pnTHNsWHdONVUtTGp6RW1pRERpTUJWU3RldElrWXR4dHI4bUpwX2dpU0NQX083SEE1eFdRd0Y?oc=5","date":"2025-07-01","type":"pipeline","source":"Fierce Biotech","summary":"BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent - Fierce Biotech","headline":"BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNWDJjOFVpTlF6aFAtdzJaQnhleEptanI5dm1jZ2U3NkxpUVVMcjdrb0ZQXzRiV3BidlJXSS1QZVQzVEN1Njk1YU1lTGplWmU1RC1EeENhVDJET2FDSVFZNTFiWV9NeFo3YTAyQTRXV3JvbHNTY1EzTzV0Y1FyRFoydHh2RC10Tm9KdVZTNU9SbWM5MXpEdzJ2cG9zd1BMZjJ1VGpNeS0tWHJWOGpXelRialV5cmhydTFicXNoWmxLSTh2b1ltWVJGTm1OaXE3YVF6dksxeHNvbGNtalhLXzFidFVGZ2MwSkJF?oc=5","date":"2025-04-08","type":"pipeline","source":"PR Newswire","summary":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - PR Newswire","headline":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}